检索结果-南通市图书馆

Lamivudine treatment of decompensated hepatitis B virus-related cirrhosis

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2006年第1期5卷 10-15页

作者： fu-kui zhang liver research center, beijing friendship hospital, capital university of medical Sciences, beijing 100050, china liver research center Beijing Friendship Hospital Capital University of Medical Sciences Beijing 100050 China. frankliver@***

BACKGROUND: Patients with decompensated hepatitis B vires (HBV)-related cirrhosis tend to have low or undetectable HBV replication. However, some patients continue to have high levels of HBV replication and effective suppression of HBV replication with antiviral agents may potentially decrease hepatic necroinflammation and improve or stabilize liver function. This review was to under stand the efficacy and safety of lamivudine in the treatment of decompensated HBV cirrhosis. DATA SOURCES: An English-language literature search (MEDLINE January 1988-July 2005) was performed, and a total of 52 articles/abstracts relevant to the issue were selected. After review of the selected papers, the meaningful results and conclusions were extracted using scientific crite ria. The papers reviewed pertained mainly to the efficacy and safety profiles of lamivudine treatment for decompensated HBV cirrhosis. RESULTS: The ultimate treatment of decompensated HBV cirrhosis is liver transplantation, but lamivudine treatment may lead to rapid suppression of viral replication and improvement of biochemical and clinical parameters, reduced morbidity and hospitalization for complications of liver disease, increased pre-transplant survival as well as reduced need for transplantation. However, viral resistance can develop after prolonged treatment with lamivudine, and breakthrough hepatitis may be fatal in few patients. Adefovir is effective for lamivudine-resistant HBV mutants. CONCLUSIONS: Antiviral therapy with lamivudine for decompensated HBV cirrhosis can be effective. However, some patients may experience a hepatitis flare with the emergence of YMDD mutants resulting in progressive worsening of liver disease, and should be referred for 'rescue' therapy with other nucleoside/nucleotide analogues such as adefovir dipivoxil.

关键词： lamivudine adefovir dipivoxil hepatitis B virus cirrhosis

Interferon-alfa in the treatment of chronic hepatitis B

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2004年第3期3卷 337-340页

作者： fu-kui zhang liver research center, beijing friendship hospital,capital university of medical Sciences, beijing 100050 , china liver research center Beijing Friendship Hospital Capital University of Medical Sciences Beijing 100050 China. frankliver@***

BACKGROUND: Interferon-alfa has been used in the treat-ment of chronic hepatitis B for more than 20 years and hasits own advantages including a definite course of therapy,no production of drug-resistant variants, and sustained effi-cacy. This review was to understand the role of interferon-alfa therapy in chronic hepatitis *** RESOURCES: An English-language literature searchusing Medscape and MEDLINE was performed and a totalof 48 articles on the treatment of chronic hepatitis with in-terferon-alfa or pegylated interferon-alfa were ***: Interferon-alfa therapy was associated with ahigher HBV DNA inhibition rate and HBeAg loss rate com-pared with controls, and it may have long-term beneficialeffects in terms of HBV clearance, reduction of hepatocel-lular carcinoma, and prolongation of survival. Pegylatedinterferon-alfa was more effective than conventional inter-feron-alfa in the treatment of chronic hepatitis B as well aschronic hepatitis C, and was also associated with greater ef-ficacy than conventional interferon in difficult-to-treat ***: Interferon-alfa is still regarded as one ofthe first-line drugs for the treatment of chronic hepatitis *** interferon is a more promising therapy than con-ventional interferon-alfa, especially in patients with refrac-tory chronic hepatitis B.

关键词： chronic hepatitis B interferon pegylated interferon lamivudine

2023 Guideline for the management of hypertension in the elderly population in china

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第6期21卷 589-630页

作者： Hypertension Branch of Chinese Geriatrics Society,beijing Hypertension Association,National Clinical research center of the Geriatric Diseases Qi HUA Li FAN Zeng-Wu WANG Jing LI 不详 Xuanwu hospital Capital Medical UniversityBeijingChina Chinese PLA General hospital BeijingChina fuwai hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Preamble Hypertension is one of the most common chronic diseases and the primary risk factor for stroke,myocardial infarction and even cardiovascular *** than half of the elderly population has high blood *** people are a unique group,and strategies for the prevention,diagnosis,evaluation,and treatment of hypertension in elderly individuals differ significantly from those in the general population.

关键词： hypertension prevention diagnosis

Clinical evaluation of serum antimitochondrial antibody-negative primary biliary cirrhosis

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2004年第2期3卷 288-291页

作者： fu-kui zhang, Ji-Dong Jia and Bao-En Wang beijing, china liver research center, beijing friendship hospital, capital university of medical Sciences, beijing 100050 , china liver research center Beijing Friendship Hospital Capital University of Medical Sciences Beijing 100050 China. frankliver@***

BACKGROUND: Primary biliary cirrhosis (PBC) is cha- racterized by frequent presence of antimitochondrial anti- bodies (AMAs). The sensitivity and specificity of AMA for PBC are both greater than 90%-95%, so the presence of AMA in serum is the major hallmark in PBC. However, it has long been recognized that in 5%-10% of patients the clinical, biochemical and histological features are diagnos- tic for PBC, but their sera are consistently tested negative for AMA/AMA-M2. This study aimed to evaluate whether the presence of AMA alters the clinical, serological and his- tological features of the disease. METHODS: Clinical data of 70 patients clinically and/or histologically diagnosed with PBC were reviewed. AMA- negative and AMA-positive patients were compared in terms of clinical, biochemical, immunological and histo- logical features. RESULTS: At presentation, 11 patients were serum AMA/ AMA-M2 negative. At the initial visit, AMA-negative and AMA-positive patients were similar in terms of age, sex, clinical manifestations, liver biochemistries and histological findings. The mean level of serum immunoglobulin M (IgM) was significantly lower in AMA-negative PBC pa- tients than in AMA-positive PBC patients (2851±1418 mg/L vs 6361 ±4928 mg/L, P =0.033). Serum antinuclear anti- bodies ( ANA) and/or smooth muscle antibodies ( SMA) were more frequently positive in the AMA-negative PBC patients than in the AMA-positive patients (81.8% vs 40.7%, P =0.031). CONCLUSION: AMA-negative PBC patients are characte- rized by relatively lower levels of serum IgM and a higher prevalence of serum ANA/SMA and are not associated with substantial differences in the clinical, biochemical and histo- logical spectrum of the disease.

关键词： primary biliary cirrhosis antimitochondrial antibody antinuclear antibody immunoglobulin M

Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected smal hepatocel ular carcinomas

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2010年第3期9卷 296-305页

作者： Jiang Long,Zhen-Wei Lang,Hua-Guang Wang,Tai-Ling Wang,Bao-En Wang and Si-Qi Liu liver research center,beijing friendship hospital, capital medical university,beijing 100050,china Department of Hepatology,Department of Pathology, beijing Youan hospital,capital medical university,beijing 100069,china Department of Pharmaceutical Affairs,beijing Chaoyang hospital,capital medical university,beijing 100020,china Department of Pathology,china-Japan friendship hospital,beijing 100029,china beijing Genomics Institute,Chinese Academy of Science,beijing Airport Industrial Zone B-6,Shunyi,beijing 101300,china liver research center Beijing Friendship Hospital Capital Medical University Beijing China.

BACKGROUND:Hepatocellular carcinoma(HCC)is a highly malignant tumor with a poor *** small HCCs possess most of the characteristics of early HCC,we investigated small HCCs to screen potential biomarkers for early ***:Proteins were extracted from 10 sets of paired tissue samples from HBV-infected small-HCC *** extracted proteins were well resolved by two-dimensional *** HCC-associated proteins were then identified by MALDI-TOF/TOF MS following image *** blotting and immunohistochemistry were used to assess glutamine synthetase(GS)and phenazine biosynthesislike domain-containing protein(PBLD)expression in liver ***-linked immunosorbent assays in 152 serum samples(from 49 healthy donors,24 patients with liver cirrhosis,and 79 with HCC)were used to further assess the significance of GS ***:Fifteen up-regulated and three down-regulated proteins were *** blotting confirmed GS overexpression and decreased PBLD expression in liver *** showed that GS was expressed in 70.0%(84/120)of HCCs and 35.8%(43/120)of nontumor tissues;PBLD was expressed in 74.2%(89/120) of nontumor tissues and 40.8%(49/120)of *** Chi-square test showed significant expression differences between HCCs and adjacent *** with this,serum GS levels in HCC patients were significantly higher than those in liver cirrhosis patients and healthy donors,while the latter two groups were also significantly *** addition, a diagnostic cutoff value of 2.6 mg/ml was used for GS;it was elevated in 19(76.0%)of 25 HCC patients with AFP≤20 ng/ml and 47(88.7%)of 53 HCC patients with AFP≤200 ng/***:GS and PBLD are abnormally expressed in most *** may be a novel serum marker for early HCC, especially for those patients with low AFP levels(≤200 ng/ml).

关键词： glutamine synthetase phenazine biosynthesis-like domain-containing protein proteomics

Information extraction and CT reconstruction of liver images based on diffraction enhanced imaging

在线全文

学校读者我要写书评

暂无评论

Progress in Natural Science:Materials International 2009年第8期19卷 955-962页

作者： Chunhong Hua,b, Tao Zhao a, Lu zhanga, Hui Lia, Xinyan Zhao c, Shuqian Luoa, a College of Biomedical Engineering, capital medical university, beijing 100069, china b National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, beijing 100080, china c liver research center, beijing friendship hospital, capital medical university, beijing 100050, china College of Biomedical Engineering Capital Medical University Beijing 100069 China National Laboratory of Pattern Recognition Institute of Automation Chinese Academy of Sciences Beijing 100080 China liver research center Beijing Friendship Hospital Capital Medical University Beijing 100050 China

X-ray phase-contrast imaging (PCI) is a new emerging imaging technique that generates a high spatial resolution and high contrast of biological soft tissues compared to conventional radiography. Herein a biomedical application of diffraction enhanced imaging (DEI) is presented. As one of the PCI methods, DEI derives contrast from many different kinds of sample information, such as the sample’s X-ray absorption, refraction gradient and ultra-small-angle X-ray scattering (USAXS) properties, and the sample information is expressed by three parametric images. Combinedwith computed tomography (CT), DEI-CT can produce 3D volumetric images of the sample and can be used for investigating micro-structures of biomedical samples. Our DEI experiments for liver samples were implemented at the topography station of beijing Synchrotron Radiation Facility (BSRF). The results show that by using our provided information extraction method and DEI-CT reconstruction approach, the obtained parametric images clearly display the inner structures of liver tissues and the morphology of blood vessels. furthermore, the reconstructed 3D view of the liver blood vessels exhibits the micro blood vessels whose minimum diameter is on the order of about tens of microns, much better than its conventional CT reconstruction at a millimeter resolution. In conclusion, both the information extraction method and DEI-CT have the potential for use in biomedical micro-structures analysis.

关键词： Diffraction enhanced imaging Computed tomography Information extraction X-ray liver

Surgical treatment of portal hypertension

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2002年第2期1卷 211-214页

作者： Yu Wang From the Department of General Surgery, beijing friendship hospital, capital university of medical Sciences, beijing 100050, china Department of General Surgery Beijing Friendship Hospital Capital University of Medical Sci. Beijing 100050 China

Portal hypertension is a common disease with high mortality and serious influence on the life quality of patients. At present, shunt and disconnection are commonly used for the treatment of portal hyperten- sion. In recent years, combined procedures of shunt and disconnection have evoked the potential interest of surgeons. Initial experimental studies and clinical observations showed that the combined procedures are ideal for treating portal hypertension. Transju- gular intrahepatic portacaval shunt (TIPS) is a new minimally invasive technique in treating portal hy- pertension. Some surgeons have tried to perform dis- connection under laparoscopy with success. liver transplantation will be the focus of portal hyperten- sion surgery in the future.

关键词： portal hypertension shunt disconnection transjugular intrahepatic portacaval shunt liver transplantation

Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases & Immunity 2024年第3期4卷 106-120页

作者： Chinese Society of Infectious Diseases Chinese medical Association Chinese Society of Hepatology Chinese medical Association Group of Infectious Diseases Chinese Pediatric Society Chinese medical Association National Clinical research center for Infectious Diseases(beijing) fu-Sheng Wang Shishu Zhu Min zhang Jianshe Wang Shuangjie Li Junliang fu Yuanyuan Li Yuming Guo Jing Li Hongmei Xu Wenxian Ouyang Yuemin Nan Sainan Shu Shuangsuo Dang Xiaoyuan Xu Taisheng Li Jinlin Hou 不详 The Fifth medical center of PLA General hospital Beijing 100039China fudan university Children’s hospital Hunan Children’s hospital Children’s hospital of Chongqing medical university Third hospital Hebei Medical University Tongji hospital Tongji Medical CollegeHuazhong University of Science and Technology The Second Affiliated hospital of Xi’an Jiaotong university Peking university First hospital Peking Union medical College hospital Chinese Academy of Medical Sciences&Peking Union Medical College Nanfang hospital Southern Medical University

The aim of this consensus is to standardize the prevention, diagnosis, and treatment of chronic hepatitis B in children and to achieve the goal of “eliminating viral hepatitis as a major public health threat by 2030” issued by the World Health Organization. Formulated by organized experts of the Chinese Society of Infectious Diseases and Chinese Society of Hepatology, Chinese medical Association;Group of Infectious Diseases, Chinese Pediatric Society, Chinese medical Association;and the National Clinical research center for Infectious Diseases (beijing), the consensus provides the latest evidence and recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B in children.

关键词： Chronic hepatitis B Children Treatment Prevention Consensus

Chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第17期137卷 2017-2039页

作者： Li Jingnan Yao Hongwei Lu Yun zhang Shutian zhang Zhongtao Society of Digestive Endoscopy of the Chinese medical Association Colorectal Surgery Group of the Chinese medical Association Chinese Association of Gastroenterologist & Hepatologist National Clinical research center for Digestive Diseases Chinese medical Journal Clinical Practie Guideline Collaborative Department of Gastroenterology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China Department of General Surgery Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Diseases Beijing China Department of General Surgery The Affiliated Hospital of Qingdao University Qingdao Shandong China Department of Gastroenterology Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Disease Beijing China

Background: The incidence and mortality of colorectal cancer (CRC) in china are increasing in recent years. The clarified pathogenesis and detectable precancerous lesions of CRC make it possible to prevent, screen, and diagnose CRC at an early stage. With the development of endoscopic and surgical techniques, the choice of treatment for early CRC is also worth further discussion, and accordingly, a standard follow-up program after treatment needs to be ***: This clinical practice guideline (CPG) was developed following the recommended process of the World Health Organization, adopting Grading of Recommendations Assessment, Development and Evaluation (GRADE) in assessing evidence quality, and using the Evidence to Decision framework to formulate clinical recommendations, thereby minimizing bias and increasing transparency of the CPG development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and Appraisal of Guidelines for research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline’s completeness and ***: This CPG comprises 46 recommendations concerning prevention, screening, diagnosis, treatment, and surveillance of CRC. In these recommendations, we have indicated protective and risk factors for CRC and made recommendations for chemoprevention. We proposed a suitable screening program for CRC based on the Chinese context. We also provided normative statements for the diagnosis, treatment, and surveillance of CRC based on existing clinical evidence and ***: The 46 recommendations in this CPG are formed with consideration for stakeholders’ values and preferences, feasibility, and acceptability. Recommendations are generalizable to resource-limited settings with similar CRC epidemiology pattern as china.

关键词： Colorectal cancer Early detection of cancer Prevention Screening Diagnosis Treatment Follow-up Guideline